CClinicalTrials.gg
CompletedNCT03894176Updated Mar 28, 2019

Association of Plasma PTX3 Concentration and Outcomes of STEMI

An observational study in STEMI and Coronary; Ischemic, sponsored by Indonesian Cardiovascular Research Center. Completed at 1 site in Indonesia. Per ClinicalTrials.gov, last updated 2019-03-28.

Sponsored by Indonesian Cardiovascular Research Center · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
335
Sex
All
01

Study summary

335 of patients with STEMI treated by primary PCI were assayed for PTX3 measurement by ELISA method. The angiographic and clinical outcomes were evaluated according to the PTX3 concentration.

Read the detailed description

335 of patients with STEMI treated by primary PCI were assayed for PTX3 measurement by ELISA method using human PTX3 kit. Blood was drawn at the emergency department before primary PCI. The angiographic and clinical outcomes were evaluated and analyzed according to the PTX3 concentration. The angiographic outcome were thrombus grade on initial angiogram and final TIMI flow. The clinical outcome were ECG resolution after primary PCI and all-cause death at 30 days. The plasma PTX3 concentration was then compared based on the outcomes.

02

Conditions studied

  • STEMI
  • Coronary; Ischemic
03

In context

ST Elevation Myocardial Infarction

667 studies on the registry are indexed under ST Elevation Myocardial Infarction; 180 are open to participants now.

This study's enrollment of 335 is close to the median of 329 across 222 observational studies indexed under ST Elevation Myocardial Infarction.

Browse ST Elevation Myocardial Infarction studies →

Lead sponsor

Indonesian Cardiovascular Research Center is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients with STEMI with symptom onset \<12 h who admiited to the emergency department and planned for primary PCI.

Inclusion criteria

  • Patients with acute STEMI with symptom onset \<12 h undergoing primary PCI

Exclusion criteria

Exclusion Criteria:

  • Acute STEMI patients who received fibrinolytic therapy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
335 participants (actual)
Patient registry
No

Groups and cohorts

  • PTX3 concentration

    First quartile, second quartile, third quartile and fourth quartile of PTX3 in ng/mL

    Other: Plasma PTX3 concentration

Interventions

  • OtherPlasma PTX3 concentration

    Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI

    Also known as: PTX3

06

What researchers measure

Primary outcomes

  1. The proportion of thrombus grade 4&5 and final TIMI flow <3

    PTX3 concentration was compared based on the outcome

    Time frame: Intraprocedure

07

Study locations

1 site
  • Indonesian Cardiovascular Research Center
    Jakarta, DKI Jakarta 11420, Indonesia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03894176
Lead sponsor
Indonesian Cardiovascular Research Center
Responsible party
Surya Dharma (Primary Investigator, Indonesian Cardiovascular Research Center) — Principal investigator
First posted
Mar 28, 2019
Start date
Jan 1, 2018
Primary completion
Aug 2, 2018
Completion
Sep 2, 2018
Last update
Mar 28, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion